S4.1-13. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for pre- vention of cardiac events following successful first percutane- ous coronary intervention: a randomized controlled trial. Jama. 2002;287:3215 22. CLINICAL STATEMENTS AND GUIDELINES S4.1-14. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911 21. S4.1-15. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. S4.1-16. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a ran- domized trial of evolocumab. N Engl J Med. 2017;377:633 43. S4.1-17. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S4.1-18. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovas- cular outcomes after acute coronary syndrome. N Engl J Med. 2018. In press. S4.1-19. Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1144 61. DOI: 10.1161/CIR.0000000000000626. S4.1-20. Hlatky MA, Kazi DS. PCSK9 inhibitors: economics and policy. J Am Coll Cardiol. 2017;70:2677 87. S4.1-21. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhi bitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743 53. S4.1-22. Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313 20. S4.1-23. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11:933 46. S4.1-24. 